Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Graff

Showing results (91-100 of 117) with videos related to

Pageof 12
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2019
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancerE J Small, F Saad, S Chowdhury, et al.
Journal for Immunotherapy of Cancer|July 4, 2020
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide aloneJulie N Graff, Tomasz M Beer, Joshi J Alumkal, et al.
JCO Precision Oncology|October 26, 2019
Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision MakingDerrick L Tao, Shawna Bailey, Tomasz M Beer, et al.
The Oncologist|May 11, 2026
A Phase I/II Trial of Concurrent Chemo-hormonal Enzalutamide and Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate CancerJulie N Graff, Claire E P Smith, Alexandra O Sokolova, et al.
NPJ Precision Oncology|September 13, 2023
Evolution of structural rearrangements in prostate cancer intracranial metastasesFrancesca Khani, William F Hooper, Xiaofei Wang, et al.
NPJ Precision Oncology|November 3, 2023
Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastasesFrancesca Khani, William F Hooper, Xiaofei Wang, et al.
Cancer Research Communications|January 5, 2026
Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer TypesYa-Mei Hu, Faming Zhao, Julie N Graff, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)Fred Saad, Kim N Chi, Neal D Shore, et al.
European Urology|September 10, 2020
Apalutamide and Overall Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
The New England Journal of Medicine|February 9, 2018
Apalutamide Treatment and Metastasis-free Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
Pageof 12

Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2019
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancerE J Small, F Saad, S Chowdhury, et al.
Journal for Immunotherapy of Cancer|July 4, 2020
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide aloneJulie N Graff, Tomasz M Beer, Joshi J Alumkal, et al.
JCO Precision Oncology|October 26, 2019
Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision MakingDerrick L Tao, Shawna Bailey, Tomasz M Beer, et al.
The Oncologist|May 11, 2026
A Phase I/II Trial of Concurrent Chemo-hormonal Enzalutamide and Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate CancerJulie N Graff, Claire E P Smith, Alexandra O Sokolova, et al.
NPJ Precision Oncology|September 13, 2023
Evolution of structural rearrangements in prostate cancer intracranial metastasesFrancesca Khani, William F Hooper, Xiaofei Wang, et al.
NPJ Precision Oncology|November 3, 2023
Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastasesFrancesca Khani, William F Hooper, Xiaofei Wang, et al.
Cancer Research Communications|January 5, 2026
Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer TypesYa-Mei Hu, Faming Zhao, Julie N Graff, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)Fred Saad, Kim N Chi, Neal D Shore, et al.
European Urology|September 10, 2020
Apalutamide and Overall Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
The New England Journal of Medicine|February 9, 2018
Apalutamide Treatment and Metastasis-free Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
Pageof 12